A
AbCellera Biologics
Innovator in antibody discovery for therapeutics, and immune profiling for vaccine research
At a glance
- Status
- Listed
- Listing
- IPO 2020
Open roles
AbCellera Biologics in the Vancouver ecosystem
The AbCellera Biologics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Series B and later7 investors entered at this stage
- NLNorthview LifeSciences
- VIViking Global Investors
- TCThe University of British Columbia
OrbiMed
Peter Thiel- ELEli Lilly
- PCPresight Capital
Source: Dealroom Talent Intelligence.
Patents
56 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Investments and acquisitions
Disclosed deals where AbCellera Biologics was the backer or acquirer, 2020–2022. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
5 deals across AbCellera Biologics's capital deployment.
Where the deals concentrate by sector, stage, and decade.
Where AbCellera Biologics deploys vs peers
Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.
AbCellera Biologics's portfolio, mapped.
See AbCellera Biologics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
AbCellera reports positive Phase 2 topline for ABCL635 in menopausal vasomotor symptoms


